메뉴 건너뛰기




Volumn 34, Issue 5, 2013, Pages 3153-3158

Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer

Author keywords

Capecitabine; Lapatinib; Metastatic breast cancer; Trastuzumab

Indexed keywords


EID: 84885427821     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0884-y     Document Type: Article
Times cited : (10)

References (17)
  • 1
    • 84864413311 scopus 로고    scopus 로고
    • Recent advances in novel targeted therapies for HER2-positive breast cancer
    • 22824822 10.1097/CAD.0b013e328352d292 1:CAS:528:DC%2BC38XhtVGnur3E
    • Murphy CG, Morris PG. Recent advances in novel targeted therapies for HER2-positive breast cancer. Anticancer Drugs. 2012;23:765-76.
    • (2012) Anticancer Drugs , vol.23 , pp. 765-776
    • Murphy, C.G.1    Morris, P.G.2
  • 2
    • 33845886440 scopus 로고    scopus 로고
    • Lapatinib plus capecitabine for HER2-positive advanced breast cancer
    • 17192538 10.1056/NEJMoa064320 1:CAS:528:DC%2BD2sXhslSqsA%3D%3D
    • Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-43.
    • (2006) N Engl J Med , vol.355 , pp. 2733-2743
    • Geyer, C.E.1    Forster, J.2    Lindquist, D.3    Chan, S.4    Romieu, C.G.5    Pienkowski, T.6
  • 4
    • 80053362290 scopus 로고    scopus 로고
    • Loibl S; GBG 26/BIG 03-05 study group and participating investigators. Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer
    • 10.1016/j.ejca.2011.06.021
    • von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, et al. Loibl S; GBG 26/BIG 03-05 study group and participating investigators. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer. 2011;47:2273-81.
    • (2011) Eur J Cancer , vol.47 , pp. 2273-2281
    • Von Minckwitz, G.1    Schwedler, K.2    Schmidt, M.3    Barinoff, J.4    Mundhenke, C.5    Cufer, T.6
  • 5
    • 84861516765 scopus 로고    scopus 로고
    • Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: Mechanisms and clinical implications
    • 22471661 10.1615/CritRevOncog.v17.i1.20
    • Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog. 2012;17:1-16.
    • (2012) Crit Rev Oncog , vol.17 , pp. 1-16
    • Rexer, B.N.1    Arteaga, C.L.2
  • 6
    • 79959226810 scopus 로고    scopus 로고
    • Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: Evidence from a retrospective study
    • 21479926 10.1007/s10549-011-1484-4 1:CAS:528:DC%2BC3MXnsVWlsr0%3D
    • Campiglio M, Bufalino R, Sandri M, Ferri E, Aiello RA, De Matteis A, et al. Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. Breast Cancer Res Treat. 2011;128:147-54.
    • (2011) Breast Cancer Res Treat , vol.128 , pp. 147-154
    • Campiglio, M.1    Bufalino, R.2    Sandri, M.3    Ferri, E.4    Aiello, R.A.5    De Matteis, A.6
  • 7
    • 0033402622 scopus 로고    scopus 로고
    • Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer
    • 10643536 10.1023/A:1008318523058 1:STN:280:DC%2BD3c7gvVWnug%3D%3D
    • Spielmann M, Llombart A, Zelek L, Sverdlin R, Rixe O, Le Cesne A. Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer. Ann Oncol. 1999;10:1457-60.
    • (1999) Ann Oncol , vol.10 , pp. 1457-1460
    • Spielmann, M.1    Llombart, A.2    Zelek, L.3    Sverdlin, R.4    Rixe, O.5    Le Cesne, A.6
  • 8
    • 0038200673 scopus 로고    scopus 로고
    • Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/relapsed metastatic breast cancer
    • 12852694 10.1080/02841860310010709 1:CAS:528:DC%2BD3sXosFCntrg%3D
    • Airoldi M, Cattel L, Pedani F, Marchionatti S, Tagini V, Bumma C, et al. Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/relapsed metastatic breast cancer. Acta Oncol. 2003;42:186-94.
    • (2003) Acta Oncol , vol.42 , pp. 186-194
    • Airoldi, M.1    Cattel, L.2    Pedani, F.3    Marchionatti, S.4    Tagini, V.5    Bumma, C.6
  • 9
    • 36849071808 scopus 로고    scopus 로고
    • Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
    • 17968020 10.1200/JCO.2007.12.6557 1:CAS:528:DC%2BD2sXhsVKnsbzO
    • Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25:5210-7.
    • (2007) J Clin Oncol , vol.25 , pp. 5210-5217
    • Thomas, E.S.1    Gomez, H.L.2    Li, R.K.3    Chung, H.C.4    Fein, L.E.5    Chan, V.F.6
  • 10
    • 77955448465 scopus 로고    scopus 로고
    • Hurtado de Mendoza F, Xu B, Vahdat LT, Peck RA, Mukhopadhyay P, Roché HH. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes
    • 20454927 10.1007/s10549-010-0901-4 1:CAS:528:DC%2BC3cXnsFymu7g%3D
    • Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, et al. Hurtado de Mendoza F, Xu B, Vahdat LT, Peck RA, Mukhopadhyay P, Roché HH. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat. 2010;122:409-18.
    • (2010) Breast Cancer Res Treat , vol.122 , pp. 409-418
    • Hortobagyi, G.N.1    Gomez, H.L.2    Li, R.K.3    Chung, H.C.4    Fein, L.E.5    Chan, V.F.6
  • 11
    • 84962735244 scopus 로고    scopus 로고
    • Pertuzumab: A step forward in treating HER2-positive breast cancer
    • Mavroudis D. Pertuzumab: a step forward in treating HER2-positive breast cancer. Transl Cancer Res. 2012;1:117-8.
    • (2012) Transl Cancer Res , vol.1 , pp. 117-118
    • Mavroudis, D.1
  • 12
    • 84866867372 scopus 로고    scopus 로고
    • The evolution of the role of surgery in the management of breast cancer lung metastasis
    • 22934145
    • Rashid OM, Takabe K. The evolution of the role of surgery in the management of breast cancer lung metastasis. J Thorac Dis. 2012;4:420-4.
    • (2012) J Thorac Dis , vol.4 , pp. 420-424
    • Rashid, O.M.1    Takabe, K.2
  • 14
    • 34548071359 scopus 로고    scopus 로고
    • Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network
    • 17699871 10.1158/1078-0432.CCR-07-0701 1:CAS:528:DC%2BD2sXptVGmtLg%3D
    • Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res. 2007;13:4909-19.
    • (2007) Clin Cancer Res , vol.13 , pp. 4909-4919
    • Ritter, C.A.1    Perez-Torres, M.2    Rinehart, C.3    Guix, M.4    Dugger, T.5    Engelman, J.A.6
  • 15
    • 33847369020 scopus 로고    scopus 로고
    • Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor i signaling
    • 17308062 10.1158/1535-7163.MCT-06-0423 1:CAS:528:DC%2BD2sXhvVWrsbc%3D
    • Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther. 2007;6:667-74.
    • (2007) Mol Cancer Ther , vol.6 , pp. 667-674
    • Nahta, R.1    Yuan, L.X.2    Du, Y.3    Esteva, F.J.4
  • 16
    • 84876907916 scopus 로고    scopus 로고
    • Optimal management of brain metastases from breast cancer: Issues and considerations
    • 23239265 10.1007/s40263-012-0024-z
    • Bartsch R, Berghoff AS, Preusser M. Optimal management of brain metastases from breast cancer: issues and considerations. CNS Drugs. 2013;27:121-34.
    • (2013) CNS Drugs , vol.27 , pp. 121-134
    • Bartsch, R.1    Berghoff, A.S.2    Preusser, M.3
  • 17
    • 84860003304 scopus 로고    scopus 로고
    • Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer
    • 22011930 10.1007/s11095-011-0601-8 1:CAS:528:DC%2BC3MXhtleqsLbN
    • Taskar KS, Rudraraju V, Mittapalli RK, Samala R, Thorsheim HR, Lockman J, et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res. 2012;29:770-81.
    • (2012) Pharm Res , vol.29 , pp. 770-781
    • Taskar, K.S.1    Rudraraju, V.2    Mittapalli, R.K.3    Samala, R.4    Thorsheim, H.R.5    Lockman, J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.